Does sermorelin nasal spray work?

There is no human study showing that a sermorelin nasal spray produces a useful result. The measured absorption is about 3 to 5 percent of a dose, and the one six-month trial, in eight children, found the response faded within weeks while antibodies and nasal irritation appeared. Height velocity over those six months did not increase.

Is sermorelin nasal spray FDA-approved?

No. Every sermorelin product FDA has ever approved was an injection, and no FDA-approved sermorelin product is currently marketed — the two Geref approvals were withdrawn effective June 18, 2009, for reasons other than safety or effectiveness. A compounded sermorelin formulation is not FDA-approved either. A licensed provider may still prescribe a compounded formulation when they judge it appropriate.

How much sermorelin is absorbed through the nose?

About 3 to 5 percent, in the study that measured it directly in thirty healthy men. Adding a surfactant to loosen the nasal lining raised a comparable figure to roughly 7 percent in a separate six-man study. For comparison, the same surfactant took a different hormone, CRH, to 100 percent of its intravenous effect — the shortfall is specific to this molecule.

Why does the nose absorb sermorelin so poorly?

Two reasons, mostly. Sermorelin is a 29-amino-acid peptide, which is large for a lining that handles small molecules well and big ones badly. And nasal mucus is continuously swept toward the throat and swallowed, so a spray has a short window before it is cleared, while enzymes in the lining break peptides apart in the meantime.

Can you take sermorelin without injections?

Compounded sermorelin is prepared in various dosage forms, but the published human evidence sits with the injected route. Swallowed and under-the-tongue forms run into the same absorption question from a different direction, and no human study has established reliable delivery by those routes either. Which form a prescriber writes for is a clinical decision, made after they review your history.

Sermorelin Nasal Spray: What Gets Past Your Nose

A sermorelin nasal spray is easy to find online and hard to absorb. That is the honest short answer. When researchers measured how much of a nasal dose reached the bloodstream, it was about 3 to 5 percent — so you would need something like fifty times the injected amount for the same effect. Sermorelin has been studied as an injection for forty years. As a spray it was tried, then largely set aside, and the reasons are worth knowing before you spend money on one.

Why the nose seemed like the obvious shortcut

Nobody enjoys injections, so the appeal is obvious.

Sermorelin is a peptide — a short chain of amino acids, 29 of them — which is a roundabout way of saying it is a very small protein. Swallow a protein and your digestion takes it apart, which is why nobody sells an insulin pill. The nose sidesteps that: the lining inside your nostrils is thin, it sits on a dense bed of blood vessels, and what gets absorbed there goes almost straight into circulation. Nasal calcitonin and desmopressin are real products built on that reasoning.

The catch is size, and a clock. The nose absorbs small molecules readily and large ones poorly, and 29 amino acids is large by that standard. Nasal mucus is also swept constantly toward the throat and swallowed, so a spray has a short window before it is carried away, while enzymes in the lining break peptides apart on contact. Sermorelin tablets run into the same argument in a different location.

What happened when someone measured a sermorelin nasal spray

Somebody did measure it, which is the useful part.

In a 1993 study, thirty healthy men were given GHRH(1-29)-NH₂ — the technical name for sermorelin — either into a vein or into the nose, and researchers compared how much turned up in the blood each way. The nasal route delivered 3 to 5 percent (Wilton et al., Acta Paediatrica 1993). Matching the growth hormone response of one microgram per kilogram given intravenously took about fifty micrograms per kilogram sprayed. A University of Virginia team had landed in the same place seven years earlier (Vance et al., 1986).

People tried to fix it. In a 1989 study of six men, a surfactant — a detergent-like compound that loosens the nasal lining so more gets through — lifted nasal GHRH to about 7 percent of the intravenous effect (Pontiroli et al., Journal of Clinical Endocrinology & Metabolism 1989). Better, still small. The revealing part is what the same surfactant did for a different hormone in the same six men: nasal CRH reached 100 percent of its intravenous effect. The nose is not a dead end in general. It is a dead end for this molecule.

The six months of nasal sermorelin that did get tried

Poor absorption is sometimes a problem you can solve by spraying more. Somebody tried that too. In the same 1993 volume, a group at the University of Kiel gave eight short prepubertal children nasal sermorelin three times a day for six months, at the high dose the absorption work had pointed to (Hümmelink et al., Acta Paediatrica 1993). On day one it behaved as intended, with clear peaks of both the peptide and growth hormone.

Then it stopped behaving. By six weeks the peaks were smaller in most of the children, smaller still by six months. Three of the eight had developed antibodies against GHRH by week six, having had none at the start. Most reported sneezing straight after a dose, a runny nose and mild burning; two came off treatment early. A sensitive short-term measure of lower-leg growth roughly doubled over the first six weeks, then fell away — and height velocity across the full six months, the number that matters, did not increase at all.

The authors concluded that nasal GHRH, convenient as it was, was not suitable in that form. That is not a competitor's verdict. It is the people who ran the study describing what they found.

The largest test of the idea: 126 children, 48 weeks

One much bigger trial tested the underlying idea, using a different compound.

Japanese researchers ran a double-blind, placebo-controlled study of a nasal spray containing GHRP-2, a growth hormone-releasing peptide that works through a different receptor than sermorelin does. They enrolled 126 short children with growth hormone deficiency — and here is the detail that matters: every child had already shown a rise in growth hormone after a test dose, so the spray was demonstrably getting in before the trial began.

Then it ran twice daily against placebo for 48 weeks. After nearly a year, the change in height score was 0.07 in the placebo group, 0.03 on the low dose and 0.02 on the high dose — no meaningful separation. IGF-1, the downstream marker growth hormone is supposed to raise, did not shift either (Tanaka et al., Clinical Pediatric Endocrinology 2014). The authors' explanation was blunt: the total growth hormone the spray generated over time was too small to produce a biological effect.

That trial is not about sermorelin and should not be read as though it were. What it tests is the premise underneath every nasal growth hormone spray sold — that a spray can lift growth hormone enough to matter — and under about the most favourable conditions anyone has arranged, it did not.

What a sermorelin nasal spray is, and what it is not

This is the part that is easiest to get wrong.

No sermorelin nasal spray has ever been an approved medicine in the United States. FDA's drug records hold exactly two sermorelin applications, both from one company, and both are injections: Geref, approved in 1990 for growth hormone testing and again in 1997 for treatment in children. No FDA-approved sermorelin product is currently marketed at all — both approvals were withdrawn effective June 18, 2009 (Federal Register, May 19, 2009) — and the compounded formulation offered here is not FDA-approved. FDA later determined Geref was pulled for reasons other than safety or effectiveness (Federal Register, March 4, 2013).

So a spray sold under this name is not a discontinued medicine that resurfaced. What any particular one holds, and whether it stays stable in a bottle, are questions no published route-specific testing answers. Compounded dosage forms vary by pharmacy and prescription, and a spray from a site that never asked for a prescription is different again — can you buy peptides over the counter covers that.

What the injection evidence looks like next to it

None of this makes sermorelin itself an open question — the injected version has a real, if modest, evidence base, which does sermorelin work goes through properly.

As of September 6, 2026, the day this article was written, the newest overview of this class is a review published on June 18, 2026 in Frontiers in Endocrinology, sorting growth hormone-axis peptides into tiers by how much human evidence stands behind each (Dominikowski et al., 2026). Its table lists intravenous and subcutaneous routes, although older human studies also tested intranasal GHRH(1–29)-NH₂ (Wilton et al., 1993, Hümmelink et al., 1993, and Vance et al., 1986). It also puts sermorelin's half-life in blood at roughly four minutes, part of why the drug is given as a known quantity rather than however much survives a nostril. The same review covers CJC-1295 and ipamorelin on those terms, the other pairing a prescriber might raise here; sermorelin versus CJC-1295 compares those directly.

How a provider decides which form to prescribe

Choosing a form is really a choice about which version behaves predictably. With an injection, the amount reaching circulation is known, so if the result is not what was expected, the dose is a variable you can reason about. With a spray, the delivered amount is unknown, and the two long studies suggest it drifts over time as well. That makes it hard to tell a treatment that is not working from one that is not arriving.

Promise offers sermorelin one way, as an injectable vial, prescribed only after a licensed provider has read your medical history — and not everyone qualifies. Whether a compounded formulation makes sense for you, and in what form, is a decision for you and your prescriber to reach together.